Introduction: What they say
A recent study from Division of Pharmacology, Department Neuroscience, School of Medicine, Federico II University, Italy shows that “MicroRNA-103-1 Selectively Downregulates Brain NCX1 and Its Inhibition by Anti-miRNA Ameliorates Stroke Damage and Neurological Deficits.” This study was published, in the July 22 2014 issue of the journal Molecular Therapy, by Prof Pignataro Giuseppe, Antonio Vinciguerra, and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based therapy for Stroke and Neurological deficits: MiRNA-380-5p ameliorates stroke damage and neurological deficits via up regulation of brain Na+/Ca2+ exchanger (NCX1).
From research findings to therapeutic opportunity:
This study suggests that Long ncRNA Gas5, by decreasing the expression of of its target gene, it may: (1) increase the expression of NCX-1; (2) ameliorate brain damage; and (3) neurological deficits. Together, this study suggests that pharmacological formulations encompassing “Long ncRNA Gas5 or its activators either alone or in combination with other drugs” may be used to treat patients suffering from stroke and neurological deficits.
Details of the idea posted:
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
For purchase and payment details, you may reach us at email@example.com
# Research cooperation
Citation: Boominathan, MiRNA-based therapy for Stroke and Neurological deficits: Long ncRNA Gas5 ameliorates stroke damage and neurological deficits via up regulation of brain Na+/Ca2+ exchanger (NCX1), 17/April/2017, 11.14 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org